Inmune Bio Business Summary

Inmune Bio, Inc. (INMB) is a clinical-stage biotechnology company that operates on a pre-revenue research and development model, focusing on the reprogramming of the innate immune system to treat neurodegenerative diseases, rare conditions, and cancer. The company’s primary business segments are built around three proprietary platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, led by XPro1595 for Alzheimer’s disease; the CORDStrom platform, an allogeneic mesenchymal stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB); and the INKmune platform for natural killer (NK) cell priming in oncology. As of early 2026, the company is transitioning toward a commercial-stage entity, with planned regulatory filings for CORDStrom in the UK and US. INmune Bio competes directly with clinical-stage peers such as ImmunityBio, Inhibikase Therapeutics, and vTv Therapeutics, positioning itself as a specialized leader in selective soluble TNF inhibition, which aims to reduce chronic inflammation without the broad immunosuppression associated with traditional TNF blockers. The company was co-founded by a veteran team of clinicians and financial strategists, including Dr. Raymond J. Tesi, David J. Moss, and Professor Mark Lowdell. The current leadership is headed by CEO David J. Moss, a former venture capitalist and founding investor with an MBA from Rice University, who succeeded co-founder RJ Tesi in 2025. Chief Scientific Officer and Chief Manufacturing Officer Professor Mark Lowdell provides deep academic pedigree as a Professor of Cell and Tissue Therapy at University College London and a recipient of the ISCT Career Achievement Award. The executive team is rounded out by Interim CFO Cory Ellspermann, a CPA with nearly 30 years of experience including a tenure at Ernst & Young. Notable institutional support includes significant stakes from Xencor, BlackRock, and Vanguard, while the Board of Directors is chaired by J. Kelly Ganjei, the CEO of AmplifyBio and a veteran of the cell and gene therapy sectors.